Jyothy Labs Q2 EBITDA margin at 2.5% amid input cost inflation

Jyothy Labs Limited reported a 2.5% operating EBITDA margin in Q2 FY27, with Rs 19.2 crore on Rs 760 crore of revenue, as inflation in crude derivatives, palm oil, chemicals and packaging materials, alongside higher-cost inventory consumption, significantly affected profitability in the quarter ended September 30, 2026.

Why was Jyothy Labs' Q2 FY27 margin 2.5%?

Jyothy Labs said its 2.5% operating earnings before interest, tax, depreciation and amortisation, or EBITDA, margin in Q2 FY27 reflected significant input-cost inflation and consumption of higher-cost inventories. The company identified crude derivatives, palm oil, chemicals and packaging materials as the main cost pressures during the quarter ended September 30, 2026.

Jyothy Labs reported Rs 19.2 crore of operating EBITDA and Rs 10.6 crore of profit after tax in Q2 FY27. Revenue from operations was Rs 760 crore, representing 3.3% reported value growth year on year, while the company said consumer-affordability pressure also weighed on industry profitability.

H1 FY27 operating EBITDA margin was 5.5%, compared with 2.5% in Q2 FY27, while first-half revenue from operations was Rs 1,533 crore and profit after tax was Rs 58.2 crore. The H1 figure is not a standalone previous-quarter comparison because the six-month period includes Q2, but it provides the broader disclosed result alongside the quarter's stated inventory and commodity-cost effects.

How fast did Jyothy Labs' underlying business grow in Q2 FY27?

Jyothy Labs' revenue excluding the Pril and Fa businesses grew 12.4% in value and 8.1% in volume in Q2 FY27. This underlying measure was ahead of the 3.3% reported value growth in revenue from operations, which reached Rs 760 crore during the quarter.

For H1 FY27, revenue excluding Pril and Fa grew 10.2% in value and 6.2% in volume, compared with Q2's 12.4% value and 8.1% volume growth. Jyothy Labs attributed the quarterly momentum to Fabric Care, the Exo franchise, new product launches and improving contributions from emerging trade channels.

Jyothy Labs said the broader fast-moving consumer goods environment remained uneven in the quarter ended September 30, 2026, with rural consumption outperforming urban markets. The company said early signs of urban recovery were encouraging, although affordability pressure continued alongside raw-material and packaging-cost inflation.

Which Jyothy Labs segments drove Q2 FY27 growth?

Jyothy Labs' Home Care segment recorded the fastest disclosed underlying growth in Q2 FY27, at 15.3% in value and 13.1% in volume excluding Pril sales. Fabric Care delivered 10.4% value growth and 6.4% volume growth, while Personal Care reported 11.2% value growth with a marginal volume decline.

Fabric Care growth was broad-based, according to Jyothy Labs, with liquid detergents leading category growth across Henko, Ujala, Morelight and Mr. White. Detergent powders and bars also maintained momentum, while Ujala Young and Fresh fabric conditioner gained traction during Q2 FY27.

Within Home Care, Jyothy Labs said the Exo franchise benefited from expanding distribution, while the newly launched bio enzyme-based Exo Dishwash Liquid received an encouraging consumer response. The company also introduced Maxo Agarbatti with a government-approved mosquito-control formulation and said it was working to improve product mix and profitability in Household Insecticides.

What is Jyothy Labs doing to restore margins?

Jyothy Labs said it plans to restore margins progressively through calibrated pricing, procurement efficiencies, value engineering, improved product mix and cost discipline. Management said these measures are intended to address the Q2 FY27 inflation in commodities and packaging while protecting consumer demand and brand competitiveness.

The company also plans to strengthen core brands, accelerate product launches and expand distribution through traditional and emerging channels. In Personal Care, Jyothy Labs introduced Margo Gentle glycerine bathing soap in Argan Oil and Moringa Oil variants in select markets during the quarter.

Chairperson and Managing Director M. R. Jyothy said management remains confident of sustaining double-digit underlying value growth in coming quarters. This is management's stated outlook rather than a formal margin forecast, and the release cited Q2 FY27 underlying value growth of 12.4% excluding Pril and Fa.

What do Jyothy Labs' H1 FY27 results show?

Jyothy Labs reported H1 FY27 revenue from operations of Rs 1,533 crore, up 3.1% in reported value year on year, with operating EBITDA of Rs 83.9 crore and profit after tax of Rs 58.2 crore. Its H1 operating EBITDA margin was 5.5%, compared with the 2.5% reported for Q2 FY27.

Excluding Pril and Fa, H1 FY27 revenue rose 10.2% in value and 6.2% in volume. The first-half underlying growth rates were below Q2's 12.4% value and 8.1% volume growth, while the release did not provide a separate Q1 FY27 margin or profit figure.

Jyothy Labs also said its balance sheet provides flexibility for organic and selective inorganic growth opportunities while maintaining discipline in capital allocation. The release did not disclose an acquisition target, transaction value or timetable for any inorganic opportunity.

Conclusion

Jyothy Labs combined 12.4% underlying value growth and 8.1% volume growth excluding Pril and Fa in Q2 FY27 with a 2.5% operating EBITDA margin. The contrast reflects the effect of higher commodity, chemical and packaging costs, plus higher-cost inventory consumption, on Rs 19.2 crore of quarterly operating EBITDA.

The next disclosure to watch is whether management's calibrated pricing, procurement efficiencies, value engineering, product-mix actions and cost discipline support the progressive margin recovery it has outlined. Jyothy Labs also plans further product launches, brand investment and distribution expansion while management targets double-digit underlying value growth in coming quarters.